ストックスクリーナーアプリを入手
2.28
1.30%
-0.03
アフターアワーズ：
2.30
0.02
+0.88%
前日終値:
$2.31
開ける：
$2.33
24時間の取引高:
1.35M
Relative Volume:
0.29
時価総額：
$414.17M
収益：
-
当期純損益:
$-110.78M
株価収益率:
-2.1308
EPS:
-1.07
ネットキャッシュフロー:
$-75.59M
1週間 パフォーマンス:
+2.70%
1か月 パフォーマンス:
-12.64%
6か月 パフォーマンス:
-55.29%
1年 パフォーマンス:
-59.79%
1日の値動き範囲:
$2.235
$2.3492
1週間の範囲:
$2.08
$2.395
52週間の値動き範囲:
$1.15
$9.79
Humacyte Inc Stock (HUMA) Company Profile
名前
Humacyte Inc
セクター
電話
919-313-9633
住所
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.28 | 414.17M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-14 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-05-16 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 開始されました | Cowen | Outperform |
| 2021-09-24 | 開始されました | Oppenheimer | Outperform |
| 2021-09-22 | 開始されました | BTIG Research | Buy |
| 2021-09-16 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Humacyte Inc (HUMA) 最新ニュース
Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know - Yahoo Finance
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
Humacyte: Revenue Ramp From Symvess Incoming (NASDAQ:HUMA) - Seeking Alpha
Humacyte (HUMA) Maintains "Buy" Rating with $25 Price Target | H - GuruFocus
Humacyte (HUMA) Phase 3 Trial Highlights Advantages of Engineered Vessel for Hemodialysis | HUMA Stock News - GuruFocus
Humacyte, Inc. Announces the Results from Its V007 Pivotal Phase 3 Clinical Trial of the Acellular Tissue Engineered Vessel - MarketScreener
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting - The Manila Times
Phase 3 Trial: Humacyte Vessel Outperforms Standard Dialysis Access in High-Risk Patients | HUMA Stock News - Stock Titan
Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey (NASDAQ:HUMA) - Seeking Alpha
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in May - Defense World
Nuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Cetera Investment Advisers Buys 9,134 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte (HUMA) to Present Phase 3 Trial Results at Vascular Sur - GuruFocus
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 - TradingView
Breakthrough: Humacyte's Bioengineered Vessel Outperforms Standard Treatment in Phase 3 Dialysis Trial - Stock Titan
Humacyte, Inc. (NASDAQ:HUMA) Shares Acquired by ProShare Advisors LLC - Defense World
BNP Paribas Financial Markets Buys Shares of 14,613 Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DE - Defense World
Deutsche Bank AG Purchases 26,419 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - MSN
Millennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
$HUMA - Binance
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Northern Trust Corp Purchases 92,708 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Is Humacyte (NASDAQ:HUMA) A Risky Investment? - simplywall.st
Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average PT from Brokerages - Defense World
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess By Investing.com - Investing.com Nigeria
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess - Investing.com Australia
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq - The Manila Times
Humacyte CEO Reveals Latest Bioengineered Tissue Developments at Elite Nasdaq Conference - Stock Titan
Price T Rowe Associates Inc. MD Has $172,000 Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
What is HC Wainwright’s Estimate for Humacyte Q2 Earnings? - Defense World
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock News - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Humacyte Inc (HUMA) 財務データ
収益
当期純利益
現金流量
EPS
Humacyte Inc (HUMA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sander Dale A. | CFO and Chief Corp. Deve. Off. |
Apr 10 '25 |
Buy |
1.53 |
20,000 |
30,600 |
40,600 |
| Parikh Shamik J | Chief Medical Officer |
Apr 10 '25 |
Buy |
1.55 |
7,500 |
11,625 |
7,500 |
| Sebelius Kathleen | Director |
Apr 08 '25 |
Buy |
1.32 |
50,000 |
66,000 |
91,207 |
| Green Charles Bruce | Director |
Apr 08 '25 |
Buy |
1.29 |
6,000 |
7,740 |
8,400 |
| Constantino Michael T. | Director |
Apr 07 '25 |
Buy |
1.26 |
16,000 |
20,160 |
32,950 |
| Constantino Michael T. | Director |
Dec 04 '24 |
Buy |
4.39 |
4,600 |
20,181 |
16,950 |
| Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
| Dougan Brady W | Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
| Niklason Laura E | President, CEO and Director |
Nov 18 '24 |
Sale |
4.44 |
811,172 |
3,601,604 |
2,419,712 |
| Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Sale |
4.34 |
427,459 |
1,855,172 |
1,992,253 |
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):